Taiho’s TS-1 Failed to Significantly Improve Survival of Patients in Second-Line Treatment

Taiho Pharmaceutical said on September 11 that a PIII study failed to demonstrate the superiority of an anticancer drug combination of TS-1 (tegafur + gimeracil + oteracil potassium) and CPT-11 (irinotecan) over CPT-11 alone in the survival of unresectable or...read more